Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease
John A Marwick1, Kian Fan Chung, Ian M Adcock
1Section of Airways Disease, National Heart and Lung Institute, Imperial College London, London, UK. j.marwick@imperial.ac.uk
Abstract:
Respiratory diseases such as chronic obstructive pulmonary disease [COPD], severe asthma, cystic fibrosis [CF] and idiopathic pulmonary fibrosis [IPF] are inadequately controlled by current therapies. The underlying molecular mechanisms and pathogenesis of these diseases remain unclear, making identification and validation of potential new therapeutic targets difficult. However, recent studies have identified the central signalling mediator PI3K as playing an integral role in the immune system including initiation and maintenance of inflammatory responses. Specifically, the relatively leukocyte-specific PI3Kgamma and PI3Kdelta isoforms are central to leukocyte function and can be targeted pharmacologically. Early to man studies using selective PI3K isoform inhibitors are required to determine whether they have a future in treating respiratory disease, particularly in controlling both innate and adaptive inflammatory responses as well as restoring glucocorticoid function and reducing tumorigenesis.
Insights
Phosphoinositide 3-kinase (PI3K) signaling is crucial for immune responses in respiratory diseases like COPD and asthma. Targeting PI3Kgamma and PI3Kdelta may offer new therapeutic strategies for these conditions.
Area of Science:
- Immunology
- Pharmacology
- Respiratory Medicine
Background:
- Current therapies inadequately control chronic obstructive pulmonary disease (COPD), severe asthma, cystic fibrosis (CF), and idiopathic pulmonary fibrosis (IPF).
- The molecular mechanisms and pathogenesis of these respiratory diseases are not fully understood, hindering the identification of new therapeutic targets.
Purpose of the Study:
- To investigate the role of phosphoinositide 3-kinase (PI3K) signaling in the immune system and its potential as a therapeutic target for respiratory diseases.
- To explore the specific involvement of leukocyte-specific PI3Kgamma and PI3Kdelta isoforms in inflammatory responses.
Main Methods:
- Review of recent studies identifying PI3K as a central signaling mediator in immune responses.
- Focus on pharmacologically targeting leukocyte-specific PI3Kgamma and PI3Kdelta isoforms.
Main Results:
- PI3K plays an integral role in the initiation and maintenance of inflammatory responses.
- PI3Kgamma and PI3Kdelta are central to leukocyte function and can be targeted pharmacologically.
Conclusions:
- Early clinical studies using selective PI3K isoform inhibitors are necessary to evaluate their therapeutic potential in respiratory diseases.
- Targeting PI3K may help control innate and adaptive inflammatory responses, restore glucocorticoid function, and reduce tumorigenesis in respiratory conditions.
More Related Videos
10:52Radiolabeling and Quantification of Cellular Levels of Phosphoinositides by High Performance Liquid Chromatography-coupled Flow Scintillation
Published on: January 6, 2016
09:22Absolute Quantitation of Inositol Pyrophosphates by Capillary Electrophoresis Electrospray Ionization Mass Spectrometry
Published on: August 13, 2021
Related Concept Videos
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
PI3K/mTOR/AKT Signaling Pathway
IP3/DAG Signaling Pathway
Respiratory Syncytial Virus Disease
The JAK-STAT Signaling Pathway
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
